EGFR and non-small cell lung carcinoma: These advances in therapeutic options for EGFR has further spurred greater understanding of NSCLC biology to reveal multiple distinct molecular subtypes—a widely supported theory that oncogenic “driver mutations” are responsible for NSCLC’s malignant phenotype [15].